Close menu




May 19th, 2021 | 08:39 CEST

CureVac, The Place Holdings, TUI - New start with great potential!

  • Investments
Photo credits: pixabay.com

Finally! Due to the positive development of the vaccination program and the successful testing strategy, the incidence figures in Germany are gradually decreasing. Industries that suffered heavily from the pandemic, such as tourism and air travel, are breathing a sigh of relief. While Germans are still planning more domestic vacations during the Whitsun vacations, bookings abroad for the summer are rising disproportionately. Other countries are also increasingly focusing on domestic tourism, with considerable potential for the respective operators.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: NL0015436031 , SG1Q02920318 , DE000TUAG000

Table of contents:


    China far ahead

    While in Europe, the third wave has just been flattened out and slow steps are being taken to return to certain normality, in China, everyday life has long since returned. There is a travel boom in the Middle Kingdom, primarily within the country. According to China's Ministry of Culture and Tourism, 102 million citizens took domestic trips during the annual National Day holiday in April 2021, a figure equivalent to 94.5% of the number of trips taken during the holiday in 2019, the year before COVID-19. Tourism has become a significant contributor to China's domestic economy and is a cornerstone of the government's long-term goal of creating a consumption-driven economy.

    The emergence of an affluent middle class supports this plan. Due to the increasing economic power of consumers and the extreme inclination of the Chinese towards gaming, advertising, consumption and entertainment, the entertainment market is flourishing and new concepts are being developed. In contrast, much of China is still in a nascent phase in project and city development. Here, The Place Holdings, which is traded on the SGX in Singapore and Frankfurt, has created a perfect symbiosis of its three business segments to meet the needs of the emerging population.

    Three models in one

    The Place Holdings focuses on integrating traditional stores with omnichannel strategies and digital solutions such as "new-retail" solutions, last-mile logistics, immersive virtual reality technology, and smart connectivity for businesses to take advantage of new growth opportunities in the digital economy. The Group has built a business platform to integrate new value propositions within its 3 core businesses: real estate development and management, cultural tourism, and media-related businesses.

    To date, the debt-free Company, which has around EUR 46 million in cash, has three acquisitions in its portfolio. In the case of the Reality Centre, which was acquired in 2020 for EUR 93 million, the experienced management speculates on the claim to bonus property ratios of between 25% to 30% if a change of use occurs under the Central Business District (CBD) Incentive Scheme. The Place Holdings hold a 20% stake in MCC Land's mixed development project adjacent to the Tanah Merah MRT interchange.

    The third project, a plot of land that has only been held by a subsidiary since November, saw news of a significant revaluation last week. The size of the land is approximately 270,500.64 square meters. It is strategically located within Mount Yuntai Tourist Township, where hospitality properties, wellness resorts, integrated retail and commercial developments, and theme parks are planned and some are currently under development.

    Compared to the property's valuation of EUR 14.27 million as of September 30, 2020, the property was valued at EUR 61.29 million, up 329%, after the zoning change by one of China's leading valuation firms, which will add EUR 47.02 million to the balance sheet. Currently, the market capitalization of the Company is EUR 370.48 million. Suppose you are interested in the real estate market 2.0. in Singapore, you cannot avoid The Place Holdings. However, one should strictly limit due to the low tradability in Germany.

    When will the approval come?

    Due to the possible patent release, Panic selling gave investors a second chance with the Tübingen-based vaccine manufacturer CureVac. The share price fell from a high of EUR 110 to a low of below EUR 75. After forming a double bottom, however, the price recovered and closed the torn downward gap at around EUR 90. Yesterday, the share tested resistance at EUR 95. Breaking through the EUR 100 mark, at which the value has already failed three times on a sustained basis, is likely to be a more challenging task. Driven by the news, this could happen in June. Currently, CureVac is still in clinical trials; an application for approval should follow soon. The Tübingen-based Company is also well on schedule with its research into a second-generation vaccine that is supposed to be particularly effective against mutations. Clinical trials are expected to begin in the third quarter. If the first vaccine is approved in June, we expect a test of the old highs at EUR 125.40, at least in the short term.

    Hope dies last

    From summer, everything should get better. After further lockdowns and postponements, the travel group TUI hopes for a quick recovery of travel in the summer months. Slowly, it is also high time if one does not want to once again pump the already plundered state coffers.
    In the first two fiscal quarters of 2020/2021, from October to March, the world's largest travel provider accumulated a loss typical for the time of year. Still, at just under EUR 1.48 billion, this was more than 70% higher than in the same period last year. Currently, TUI has cash and cash equivalents of EUR 1.7 billion, with a cash outflow of EUR 300 million per month at last count. The state pumped a total of EUR 4.3 billion into the Hanover-based Group to prevent insolvency. Market capitalization is currently EUR 2.87 billion. Even though the travel business is picking up again, TUI faces major challenges in the future. Due to the uncertainties, we do not recommend an investment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read